| pubmed-article:14599858 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14599858 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:14599858 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:14599858 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:14599858 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:14599858 | lifeskim:mentions | umls-concept:C1705294 | lld:lifeskim |
| pubmed-article:14599858 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:14599858 | pubmed:dateCreated | 2003-11-5 | lld:pubmed |
| pubmed-article:14599858 | pubmed:abstractText | In an effort to improve the results of primary chemotherapy for müllerian malignancies a novel chemotherapy program was piloted that delivered three sequential chemotherapy doublets. The primary endpoints were surgically defined response rates and evaluation of toxicity. | lld:pubmed |
| pubmed-article:14599858 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14599858 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14599858 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14599858 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14599858 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14599858 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14599858 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14599858 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14599858 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14599858 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14599858 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:14599858 | pubmed:issn | 0090-8258 | lld:pubmed |
| pubmed-article:14599858 | pubmed:author | pubmed-author:RocheMM | lld:pubmed |
| pubmed-article:14599858 | pubmed:author | pubmed-author:LeeHH | lld:pubmed |
| pubmed-article:14599858 | pubmed:author | pubmed-author:GoreSS | lld:pubmed |
| pubmed-article:14599858 | pubmed:author | pubmed-author:CamposSS | lld:pubmed |
| pubmed-article:14599858 | pubmed:author | pubmed-author:BerkowitzRR | lld:pubmed |
| pubmed-article:14599858 | pubmed:author | pubmed-author:FullerAA | lld:pubmed |
| pubmed-article:14599858 | pubmed:author | pubmed-author:SeidenM VMV | lld:pubmed |
| pubmed-article:14599858 | pubmed:author | pubmed-author:MatulonisUU | lld:pubmed |
| pubmed-article:14599858 | pubmed:author | pubmed-author:DuskaLL | lld:pubmed |
| pubmed-article:14599858 | pubmed:author | pubmed-author:ColellaTT | lld:pubmed |
| pubmed-article:14599858 | pubmed:author | pubmed-author:Gynecologic... | lld:pubmed |
| pubmed-article:14599858 | pubmed:author | pubmed-author:Dana... | lld:pubmed |
| pubmed-article:14599858 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14599858 | pubmed:volume | 91 | lld:pubmed |
| pubmed-article:14599858 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14599858 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14599858 | pubmed:pagination | 293-8 | lld:pubmed |
| pubmed-article:14599858 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:14599858 | pubmed:meshHeading | pubmed-meshheading:14599858... | lld:pubmed |
| pubmed-article:14599858 | pubmed:meshHeading | pubmed-meshheading:14599858... | lld:pubmed |
| pubmed-article:14599858 | pubmed:meshHeading | pubmed-meshheading:14599858... | lld:pubmed |
| pubmed-article:14599858 | pubmed:meshHeading | pubmed-meshheading:14599858... | lld:pubmed |
| pubmed-article:14599858 | pubmed:meshHeading | pubmed-meshheading:14599858... | lld:pubmed |
| pubmed-article:14599858 | pubmed:meshHeading | pubmed-meshheading:14599858... | lld:pubmed |
| pubmed-article:14599858 | pubmed:meshHeading | pubmed-meshheading:14599858... | lld:pubmed |
| pubmed-article:14599858 | pubmed:meshHeading | pubmed-meshheading:14599858... | lld:pubmed |
| pubmed-article:14599858 | pubmed:meshHeading | pubmed-meshheading:14599858... | lld:pubmed |
| pubmed-article:14599858 | pubmed:meshHeading | pubmed-meshheading:14599858... | lld:pubmed |
| pubmed-article:14599858 | pubmed:meshHeading | pubmed-meshheading:14599858... | lld:pubmed |
| pubmed-article:14599858 | pubmed:meshHeading | pubmed-meshheading:14599858... | lld:pubmed |
| pubmed-article:14599858 | pubmed:meshHeading | pubmed-meshheading:14599858... | lld:pubmed |
| pubmed-article:14599858 | pubmed:meshHeading | pubmed-meshheading:14599858... | lld:pubmed |
| pubmed-article:14599858 | pubmed:meshHeading | pubmed-meshheading:14599858... | lld:pubmed |
| pubmed-article:14599858 | pubmed:meshHeading | pubmed-meshheading:14599858... | lld:pubmed |
| pubmed-article:14599858 | pubmed:meshHeading | pubmed-meshheading:14599858... | lld:pubmed |
| pubmed-article:14599858 | pubmed:meshHeading | pubmed-meshheading:14599858... | lld:pubmed |
| pubmed-article:14599858 | pubmed:meshHeading | pubmed-meshheading:14599858... | lld:pubmed |
| pubmed-article:14599858 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:14599858 | pubmed:articleTitle | A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. | lld:pubmed |
| pubmed-article:14599858 | pubmed:affiliation | Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA. | lld:pubmed |
| pubmed-article:14599858 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14599858 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:14599858 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:14599858 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14599858 | lld:pubmed |
